OBJECTIVE: Antirheumatic treatment is frequently not appropriately modified, according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints (DAS28) score greater than 3.2. The objective of this study was to determine which factors most strongly influence patients' and rheumatologists' decisions to escalate care. METHODS: We administered a Maximum Difference Scaling survey to 106 rheumatologists and 213 patients with RA. The survey included 58 factors related to the decision to escalate care in RA. Participants answered 24 choice tasks. In each task, participants were asked to choose the most important factor from a set of 5. We used hierarchical Bayes modeling to generate the mean relative importance score (RIS) for each factor. RESULTS: For rheumatologists, the 5 most influential factors were number of swollen joints (mean ± SD RIS 5.2 ± 0.4), DAS28 score (mean ± SD RIS 5.2 ± 0.5), physician global assessment of disease activity (mean ± SD RIS 5.2 ± 0.6), worsening erosions over the last year (mean ± SD RIS 5.2 ± 0.5), and RA disease activity now compared to 3 months ago (mean ± SD RIS 5.1 ± 0.6). For patients, the 5 most important factors were current level of physical functioning (mean ± SD RIS 4.3 ± 1.1), motivation to get better (mean ± SD RIS 3.5 ± 1.4), trust in their rheumatologist (mean ± SD RIS 3.5 ± 1.6), satisfaction with current disease-modifying antirheumatic drugs (mean ± SD RIS 3.4 ± 1.4), and current number of painful joints (mean ± SD RIS 3.4 ± 1.4). CONCLUSION: Factors influencing the decision to escalate care differ between rheumatologists and patients. Better communication between patients and their physicians may improve treatment planning in RA patients with active disease.
OBJECTIVE: Antirheumatic treatment is frequently not appropriately modified, according to American College of Rheumatology guidelines, in patients with active rheumatoid arthritis (RA) as defined by a Disease Activity Score in 28 joints (DAS28) score greater than 3.2. The objective of this study was to determine which factors most strongly influence patients' and rheumatologists' decisions to escalate care. METHODS: We administered a Maximum Difference Scaling survey to 106 rheumatologists and 213 patients with RA. The survey included 58 factors related to the decision to escalate care in RA. Participants answered 24 choice tasks. In each task, participants were asked to choose the most important factor from a set of 5. We used hierarchical Bayes modeling to generate the mean relative importance score (RIS) for each factor. RESULTS: For rheumatologists, the 5 most influential factors were number of swollen joints (mean ± SD RIS 5.2 ± 0.4), DAS28 score (mean ± SD RIS 5.2 ± 0.5), physician global assessment of disease activity (mean ± SD RIS 5.2 ± 0.6), worsening erosions over the last year (mean ± SD RIS 5.2 ± 0.5), and RA disease activity now compared to 3 months ago (mean ± SD RIS 5.1 ± 0.6). For patients, the 5 most important factors were current level of physical functioning (mean ± SD RIS 4.3 ± 1.1), motivation to get better (mean ± SD RIS 3.5 ± 1.4), trust in their rheumatologist (mean ± SD RIS 3.5 ± 1.6), satisfaction with current disease-modifying antirheumatic drugs (mean ± SD RIS 3.4 ± 1.4), and current number of painful joints (mean ± SD RIS 3.4 ± 1.4). CONCLUSION: Factors influencing the decision to escalate care differ between rheumatologists and patients. Better communication between patients and their physicians may improve treatment planning in RApatients with active disease.
Authors: T Kennedy; C McCabe; G Struthers; H Sinclair; K Chakravaty; D Bax; M Shipley; R Abernethy; T Palferman; R Hull Journal: Rheumatology (Oxford) Date: 2005-02-22 Impact factor: 7.580
Authors: Lydia G Schipper; Laura T C van Hulst; Richard Grol; Piet L C M van Riel; Marlies E J L Hulscher; Jaap Fransen Journal: Rheumatology (Oxford) Date: 2010-07-29 Impact factor: 7.580
Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans Journal: Arthritis Rheum Date: 2005-11
Authors: M Ahlmén; U Nordenskiöld; B Archenholtz; I Thyberg; R Rönnqvist; L Lindén; A-K Andersson; K Mannerkorpi Journal: Rheumatology (Oxford) Date: 2004-09-20 Impact factor: 7.580
Authors: J Fransen; G Stucki; J Twisk; A-M Chamot; J-C Gerster; T Langenegger; M Seitz; B A Michel Journal: Ann Rheum Dis Date: 2003-07 Impact factor: 19.103
Authors: Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna Journal: Arthritis Care Res (Hoboken) Date: 2012-07 Impact factor: 4.794
Authors: Cynthia J Larmore; Natalie N Boytsov; Carol L Gaich; Xiang Zhang; Andre B Araujo; Sabrina Rebello; Bob A Salim; George W Reed; Leslie R Harrold Journal: Rheumatol Ther Date: 2018-01-10
Authors: Emily J Bacalao; George J Greene; Jennifer L Beaumont; Amy Eisenstein; Azra Muftic; Arthur M Mandelin; David Cella; Eric M Ruderman Journal: Clin Rheumatol Date: 2017-06-26 Impact factor: 2.980
Authors: Bee Eng Tan; Ai Lee Lim; Sow Lai Kan; Chong Hong Lim; Ying Fun Ng; Serene Li Ching Tng; Nur Syakirah Hassin; Losshenee Chandran; Norshahida Abdul Hamid; Yvonne Yin Leng Lee Journal: Rheumatol Int Date: 2017-04-07 Impact factor: 2.631
Authors: Liana Fraenkel; Cynthia K Matzko; Debra E Webb; Brian Oppermann; Peter Charpentier; Ellen Peters; Valerie Reyna; Eric D Newman Journal: Arthritis Care Res (Hoboken) Date: 2015-11 Impact factor: 4.794
Authors: Elizabeth Wahl; Andrew Gross; Vladimir Chernitskiy; Laura Trupin; Lianne Gensler; Krishna Chaganti; Kaleb Michaud; Patricia Katz; Jinoos Yazdany Journal: Arthritis Care Res (Hoboken) Date: 2017-03 Impact factor: 4.794